DB16311InvestigationalProtein Based Therapies
Ribaxamase is under investigation in clinical trial NCT02563106 (A Study of SYN-004 for the Prevention of c.diff in Patients With a LRTI).
- Mechanism
- Curator reviewed
Pharmacologically active on Epidermal growth factor receptor
- Also known as
- .beta.-lactamase (synthetic bacillus licheniformis isoenzyme syn-004)
- Code names
- P3A · SYN-004
Resolves to
Compound
Targets
What you can answer from here — as of July 08, 2026
Which drugs share a target with Ribaxamase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account